Immunotherapy in renal cell carcinoma
- PMID: 37844599
- DOI: 10.1016/S1470-2045(23)00473-4
Immunotherapy in renal cell carcinoma
Conflict of interest statement
VN reports consulting fees from Ipsen; fees or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer and Sanofi; travel expenses from Sanofi, EMD, and Serono; and participation on a data safety monitoring board or advisory board for Pfizer and AstraZeneca. DYCH reports fees or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD, Merck KGA, Novartis, and Pfizer; and consulting fees from Bristol Meyers Squibb, Exelixis, Eisai, and Ipsen.
Comment on
-
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844597 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
